NCT00883298View on ClinicalTrials.gov

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

December 1, 2014

Conditions
Recurrent Glioblastoma MultiformeRecurrent Gliosarcoma
Interventions
DRUG

temozolomide and bevacizumab

oral temozolomide 100 mg/m2 days 1-5 \& 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 \& 5 every 28-day cycle

Trial Locations (1)

85718

Center for Neurosciences, Tucson

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Center for Neurosciences, Tucson

OTHER

NCT00883298 - Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter